Literature DB >> 9135556

Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues.

J Castan1, K Tenner-Racz, P Racz, B Fleischer, B M Bröker.   

Abstract

CTLA-4, a coreceptor with sequence homology to CD28 is expressed on T cells after activation. Mice deficient for CTLA-4 die young from massive infiltration of many organs by activated T cells, which highlights the essential inhibitory role the coreceptor plays in the regulation of the immune response. To study the prevalence and distribution of CTLA-4 in situ immunohistological analyses were carried out on human tonsils and lymph nodes. Expression of CTLA-4 was restricted to alpha beta T cells, and CTLA-4+ B cells were not observed. In T-cell areas, 2-10% of T cells were positive for CTLA-4 with similar percentages in the CD4+ and CD8+ subpopulations. In the germinal centres (GC) the fraction of CTLA-4+ T cells was much higher (70-90%). This was due to frequent expression of CTLA-4 on the CD4+ helper subpopulation. GC CD8+ T cells were rare and mostly did not express the coreceptor. The CTLA-4+ T-cell fraction was also over-represented among intraepithelial tonsillar T cells. Cycling (Ki-67+) and apoptotic (TUNEL+) T cells were never positive for CTLA-4, while a subset of CD25+ cells did express the coreceptor. Since CTLA-4 is essential for the physiological limitation of the immune response, GC T cells, which are mostly CTLA-4 positive, might be important in this process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135556      PMCID: PMC1456743          DOI: 10.1046/j.1365-2567.1997.00162.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production.

Authors:  G J Freeman; D B Lombard; C D Gimmi; S A Brod; K Lee; J C Laning; D A Hafler; M E Dorf; G S Gray; H Reiser
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

Review 2.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Authors:  D L Mueller; M K Jenkins; R H Schwartz
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.

Authors:  K Harper; C Balzano; E Rouvier; M G Mattéi; M F Luciani; P Golstein
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

4.  Reactivity of presumed anti-natural killer cell antibody Leu 7 with intrafollicular T lymphocytes.

Authors:  S Poppema; L Visser; L De Leij
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

Review 5.  Life and death in germinal centers (redux).

Authors:  G Kelsoe
Journal:  Immunity       Date:  1996-02       Impact factor: 31.745

6.  A new member of the immunoglobulin superfamily--CTLA-4.

Authors:  J F Brunet; F Denizot; M F Luciani; M Roux-Dosseto; M Suzan; M G Mattei; P Golstein
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

7.  Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains.

Authors:  P Dariavach; M G Mattéi; P Golstein; M P Lefranc
Journal:  Eur J Immunol       Date:  1988-12       Impact factor: 5.532

8.  Functional analysis of cloned germinal center CD4+ cells with natural killer cell-related features. Divergence from typical T helper cells.

Authors:  A Velardi; M C Mingari; L Moretta; C E Grossi
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

9.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

10.  CTLA-4 is a second receptor for the B cell activation antigen B7.

Authors:  P S Linsley; W Brady; M Urnes; L S Grosmaire; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Germinal-center organization and cellular dynamics.

Authors:  Christopher D C Allen; Takaharu Okada; Jason G Cyster
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

2.  The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape.

Authors:  P Blancou; N Chenciner; M C Cumont; S Wain-Hobson; B Hurtrel; R Cheynier
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.

Authors:  K Steiner; I Waase; T Rau; M Dietrich; B Fleischer; B M Bröker
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

4.  Human CTLA-4 is expressed in situ on T lymphocytes in germinal centers, in cutaneous graft-versus-host disease, and in Hodgkin's disease.

Authors:  K Vandenborre; J Delabie; M A Boogaerts; R De Vos; K Lorré; C De Wolf-Peeters; P Vandenberghe
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

5.  Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis.

Authors:  K Steiner; F Moosig; E Csernok; K Selleng; W L Gross; B Fleischer; B M Bröker
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

Review 6.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

7.  Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors.

Authors:  Alireza Samiei; David W Gjertson; Sanaz Memarzadeh; Gottfried E Konecny; Neda A Moatamed
Journal:  Diagn Pathol       Date:  2022-09-14       Impact factor: 3.196

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.